Episode Details
Back to Episodes
Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
Published 1 week, 6 days ago
Description
CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines.